Rasna Therapeutics, Inc. (RASP)
USD 0.0
(900.0%)
USD 0.0
(900.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 135.98 Thousand USD | -24.59% |
| 2022 | 180.32 Thousand USD | -68.97% |
| 2021 | 581.16 Thousand USD | 14.49% |
| 2020 | 507.6 Thousand USD | 136.27% |
| 2019 | 214.83 Thousand USD | 126.99% |
| 2018 | 94.64 Thousand USD | 102.34% |
| 2017 | -4.04 Million USD | -48158.9% |
| 2016 | 8425.00 USD | 24171.43% |
| 2015 | -35.00 USD | 99.45% |
| 2014 | -6335.00 USD | 86.33% |
| 2013 | -46.34 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 302.57 Thousand USD | 46.51% |
| 2024 Q1 | 206.52 Thousand USD | 51.87% |
| 2023 Q2 | 218.18 Thousand USD | 21.48% |
| 2023 FY | 135.98 Thousand USD | -24.59% |
| 2023 Q1 | 179.6 Thousand USD | -0.4% |
| 2023 Q4 | 135.98 Thousand USD | -36.17% |
| 2023 Q3 | 213.03 Thousand USD | -2.36% |
| 2022 Q1 | 372.55 Thousand USD | -35.89% |
| 2022 FY | 180.32 Thousand USD | -68.97% |
| 2022 Q4 | 180.32 Thousand USD | 43.69% |
| 2022 Q3 | 125.49 Thousand USD | -72.92% |
| 2022 Q2 | 463.4 Thousand USD | 24.38% |
| 2021 Q1 | 576.06 Thousand USD | 13.49% |
| 2021 FY | 581.16 Thousand USD | 14.49% |
| 2021 Q3 | 733.39 Thousand USD | 23.65% |
| 2021 Q2 | 593.11 Thousand USD | 2.96% |
| 2021 Q4 | 581.16 Thousand USD | -20.76% |
| 2020 Q1 | 303.03 Thousand USD | 41.05% |
| 2020 Q4 | 507.6 Thousand USD | 15.75% |
| 2020 FY | 507.6 Thousand USD | 136.27% |
| 2020 Q3 | 438.54 Thousand USD | -2.68% |
| 2020 Q2 | 450.61 Thousand USD | 48.7% |
| 2019 Q2 | 203.07 Thousand USD | 37.73% |
| 2019 Q1 | 147.44 Thousand USD | 55.78% |
| 2019 Q3 | 199.62 Thousand USD | -1.7% |
| 2019 Q4 | 214.83 Thousand USD | 7.62% |
| 2019 FY | 214.83 Thousand USD | 126.99% |
| 2018 FY | 94.64 Thousand USD | 102.34% |
| 2018 Q4 | 94.64 Thousand USD | 564.94% |
| 2018 Q3 | -20.35 Thousand USD | 96.23% |
| 2018 Q2 | -539.39 Thousand USD | 58.06% |
| 2018 Q1 | -1.28 Million USD | 49.32% |
| 2017 Q4 | -2.53 Million USD | 22.6% |
| 2017 Q1 | -4.94 Million USD | -31.32% |
| 2017 Q2 | -4.04 Million USD | 18.06% |
| 2017 Q3 | -3.27 Million USD | 19.02% |
| 2017 FY | -4.04 Million USD | -48158.9% |
| 2016 Q4 | -3.76 Million USD | -44762.45% |
| 2016 Q2 | 4075.00 USD | -59.66% |
| 2016 Q1 | 10.1 Thousand USD | 682.92% |
| 2016 Q3 | 8425.00 USD | 106.75% |
| 2016 FY | 8425.00 USD | 24171.43% |
| 2015 Q4 | -1733.00 USD | -4851.43% |
| 2015 Q2 | -1722.00 USD | -100.7% |
| 2015 FY | -35.00 USD | 99.45% |
| 2015 Q3 | -35.00 USD | 97.97% |
| 2015 Q1 | -858.00 USD | 75.34% |
| 2014 Q4 | -3480.00 USD | 45.07% |
| 2014 Q2 | -20.82 Thousand USD | 16.59% |
| 2014 Q1 | -24.96 Thousand USD | 0.0% |
| 2014 FY | -6335.00 USD | 86.33% |
| 2014 Q3 | -6335.00 USD | 69.58% |
| 2013 FY | -46.34 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 10480.84% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 97.592% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.682% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 154.478% |
| Rebus Holdings, Inc. | 305 Thousand USD | 55.413% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 102.157% |
| Qrons Inc. | 351.42 Thousand USD | 61.304% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 78.15% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.687% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 766.351% |
| Skye Bioscience, Inc. | -5.72 Million USD | 102.377% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 99.137% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 96.698% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 66.159% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.375% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 93.935% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 85.333% |
| Mesoblast Limited | 55.85 Million USD | 99.757% |
| Marizyme, Inc. | 18.56 Million USD | 99.268% |
| Genus plc | 190.6 Million USD | 99.929% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 93.918% |
| Pharming Group N.V. | 109.8 Million USD | 99.876% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 84.192% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 88.797% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 80.002% |
| ContraFect Corporation | -6.02 Million USD | 102.257% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1.003% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 88.23% |
| IMV Inc. | 7.67 Million USD | 98.227% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 97.528% |
| MultiCell Technologies, Inc. | 90.04 USD | -150931.764% |
| ONE Bio Corp. | 9.04 Million USD | 98.496% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 118.528% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 98.95% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 90.059% |
| Q BioMed Inc. | 4.06 Million USD | 96.651% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.555% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 86.505% |
| Biomind Labs Inc. | 711.4 Thousand USD | 80.884% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.775% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 93.198% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 98.938% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 62.195% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 2.729% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -584.497% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 93.824% |
| GB Sciences, Inc. | 1.74 Million USD | 92.217% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 173.992% |
| HST Global, Inc. | 96.79 Thousand USD | -40.495% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 34.055% |
| Halberd Corporation | 144.72 Thousand USD | 6.034% |
| Enzolytics Inc. | 981.65 Thousand USD | 86.147% |
| Agentix Corp. | 37.63 Thousand USD | -261.375% |
| Resverlogix Corp. | 6.45 Million USD | 97.892% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 120.204% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.007% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.289% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 98.077% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 94.979% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 101.538% |
| AVAX Technologies, Inc. | -5.9 Million USD | 102.304% |
| Zenith Capital Corp. | 10.06 Thousand USD | -1251.242% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.013% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 32.152% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 94.301% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 17.336% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 842.379% |
| Kadimastem Ltd | -253.1 Thousand USD | 153.729% |
| Helix BioMedix, Inc. | -2.57 Million USD | 105.291% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 99.329% |
| BioStem Technologies, Inc. | 4.47 Million USD | 96.959% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 32.429% |
| LadRx Corporation | -2.03 Million USD | 106.678% |
| Cell Source, Inc. | 9.23 Million USD | 98.527% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 78.59% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 78.59% |
| NovAccess Global Inc. | 2.17 Million USD | 93.758% |
| Affymax, Inc. | -5.59 Million USD | 102.43% |
| Itoco Inc. | 228.3 Thousand USD | 40.435% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 97.257% |
| Mobile Lads Corp. | 484.23 Thousand USD | 71.917% |
| CytoDyn Inc. | 20.26 Million USD | 99.329% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 21118.393% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 1567.242% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 98.235% |
| SYBLEU INC | 473.71 Thousand USD | 71.293% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 96.949% |
| International Stem Cell Corporation | 2.59 Million USD | 94.749% |
| Bioxytran, Inc. | 1.89 Million USD | 92.839% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -117.886% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 93.765% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 96.04% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 98.41% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 82.399% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 110.879% |
| Neutra Corp. | 52.18 Thousand USD | -160.58% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 105.464% |
| PureTech Health plc | -167.19 Million USD | 100.081% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 155.527% |
| IXICO plc | -4.44 Million USD | 103.06% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 98.971% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.752% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Cellectis S.A. | -43.81 Million USD | 100.31% |